C646, as a competitive inhibitor of p300, can antagonize acetyl coenzyme a, which is the substrate of acetylation of p300 and exerts anti-tumor activity in many cancer cell lines such as prostate cancer and leukemia. Here, EP300 is linked to prostate cancer.